The B Hub
Resource Library
Welcome to our Resource Library Blog page, where you can discover valuable content tailored to your specific interests and needs. Whether you're seeking information on the latest advancements in hemophilia B treatment or looking for personal stories from individuals with hemophilia B, this is the place to be. With our convenient filter options or by exploring the dedicated hubs, you can easily access articles that resonate with you on a deeper level. Take advantage of this resource and empower yourself with knowledge and insights that are relevant to your unique journey.
Update on Be Biopharma’s BE-101 Trial
Be Biopharma has ended its Phase 1/2 BeCoMe-9 study of BE-101, an investigational cell therapy for hemophilia B.
FDA Approves Expanded Use of Pfizer’s HYMPAVZI®
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
In the News: New treatment for Hemophilia B brings hope to patients
New treatment for Hemophilia B brings hope to patients
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B
Adeno-associated virus (AAV)–mediated gene therapy has emerged as a promising treatment for hemophilia B.
An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Availability
An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Availability
Pfizer Discontinues Gene Therapy for Hemophilia B
The Coalition for Hemophilia B Responds to Pfizer’s Discontinuation of Gene Therapy for Hemophilia B
Gene Therapy
CSL Behring has announced that the first patient in the United States has received HEMGENIX®, which is currently the only approved gene therapy product for hemophilia B.